FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.

Slides:



Advertisements
Similar presentations
Monotherapy using 6-MP or azathioprine for Crohn’s disease is dead: out with the old and in with the new Stephen B. Hanauer, MD Professor of Medicine Clinical.
Advertisements

Miguel Regueiro, M.D. Professor of Medicine
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Division of GASTROENTEROLOGY & HEPATOLOGY Use and Efficacy of Fecal Transplant for Refractory Clostridium difficile in IBD Patients Edward V. Loftus, Jr.,
HIGH VALUE CARE GI CONDITIONS CHRONIC DIARRHEA EDWARD LEVINE MD OSUWMC OCTOBER 11, 2014.
Journal Club: Biologic Agents in UC, Systematic Review and Network Meta-analysis, by Danese et al., Annals 2014 Barrett G. Levesque, MD Assistant Professor.
Management of Inflammatory bowel disease 8/12/10.
Treatment of Extra-intestinal Manifestations of IBD: Case studies Alan C. Moss MD, FEBG, FACG Associate Professor of Medicine Director of Translational.
A patient with severe Crohn's disease, an ileal stricture and proximal dilation on CTE should have medical therapy first Uma Mahadevan MD Professor of.
Con: An IBD patient on a biologic and/or an immunomodulator, who develops a malignancy (solid tumor, lymphoma or skin cancer), must stop and never restart.
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
Emerging treatments in Crohn’s disease and ulcerative colitis
End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.
Long-term Safety and Effectiveness of Natalizumab STRATA MS Study.
Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,
Health Maintenance for the IBD Patient: Why, By whom, what, when & how? Sharon Dudley-Brown, PhD, CRNP, FAAN Assistant Professor School of Medicine Johns.
The Patient With Pyoderma Gangrenosum Maria T. Abreu, MD Chief, Division of Gastroenterology University of Miami Miller School of Medicine Miami, Florida.
Ghassan Wahbeh MD Associate Professor, Director IBD Program Seattle Children’s Hospital University of Washington.
When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.
Progress in Diagnosing and Treating Clostridium difficile in IBD patients Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine Director of.
Prevention of Postoperative Crohn’s disease
Joel R. Rosh, MD Director, Pediatric Gastroenterology
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
FMT in IBD Walter Reinisch Department of Medicine McMaster University Hamilton, ON.
Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.
Pediatric IBD Research
Using the Pediatric RISK and PROTECT Inception Cohorts to Define Important Clinical and Biologic Phenotypes Ted Denson, MD Cincinnati Children’s Hospital.
Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.
UC & CD are disorders of modern society: their frequency in developed countries has been increasing since the mid-20 th century. Children: CD is more prevalent.
Therapeutic algorithms for Crohn’s disease: Where are we in 2012?
Clostridium difficile Prevention and Treatment Katrina Beining & Christina Gardner Introduction Clostridium difficile (C. diff) is a gram-positive, spore-forming.
Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas NICE CG March 2011.
Inflammatory Bowel Disease Francisco A. Sylvester, MD Associate Professor of Pediatrics.
What is the Deal About FMT? Herbert L. DuPont, MD Director, Center for Infectious Diseases, University of Texas School of Public Health President, Kelsey.
“Antibiotics and corticosteroids: Indications and approaches”
Complementary and Alternative Therapies in IBD Hype or Hope?
Fecal calprotectin DR Amin Eftekhari.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.
IBD Cases Stephen B. Hanauer, MD Professor of Medicine Feinberg School of Medicine Medical Director, Digestive Health Center.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
The Microbiome and Probiotics: Fact and Fiction Ameet Parikh, MD.
You Can Never Stop a Biologic
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
A Tale of Two(?) IBDs CYMMBiosis for Cure
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
William J. Sandborn, M.D., Brian G. Feagan, M.D., Paul Rutgeerts, M.D., Ph.D., Stephen Hanauer, M.D., Jean-Frederic Colombel, M.D., Bruce E. Sands, M.D.,
Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,
MIGUEL REGUEIRO, WOLFGANG SCHRAUT, LEONARD BAIDOO, KEVIN E. KIP, ANTONIA R. SEPULVEDA, MARILYN PESCI, JANET HARRISON, SCOTT E. PLEVY GASTROENTEROLOGY 2009;136:441–450.
High frequency of early colorectal cancer in inflammatory bowel disease M W M D Lutgens, F P Vleggaar, M E I Schipper, P C F Stokkers, C J van der Woude,
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
R3. 최태웅 / Pf. 김효종 Alimentary Pharmacology & Therapeutics 19 FEB 2016 DOI: /apt.13547
N Engl J Med 2012;367: Dae youn.kim/Prof.Chang hyun Lee.
Dr Gill Watermeyer IBD Clinic Division of Gastroenterology
Seeking Treatments for PSC Out of the Desert and into the Woods
From: Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile InfectionA Randomized Trial Ann Intern Med.
From: Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile InfectionA Randomized Trial Ann Intern Med.
Bleeding and cancer risk in patients with vascular disease COMPASS Steering Committee and Investigators.
Raymond Cross, MD, MS, AGAF Associate Professor of Medicine
Illustrations in Ulcerative Colitis
Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year.
Presentation data from US VICTORY Consortium
IBDHorizons.org 3 rd IBDH Annual Conference 2018 Bell Harbor Conference Center - Seattle March 3, 2018.
Infliximab trough levels above 7 μg/mL in inflammatory bowel disease treated with infliximab: Better control of inflammation without increased risk of.
Slides compiled by Dr. Najma Ahmed
Presentation transcript:

FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine

Typical Pre-Clinical Steps in Development

Elements of Clinical Trial Design in IBD 1.Patient Selection 2.Intervention 3.Outcomes

Patient Selection

Populations in Prior FMT Trials in IBD Study Duration of Disease Disease Activity Current Meds Vaughn yrs10 (HBI)Steroids, AZA/6MP Moayyedi 2014?>4 (Mayo)Steroids, AZA/6MP, Anti-TNF Kunde S yrs30-55 (PUCAI) 5-ASA, 6MP, Steroids Kump P yrs8-11 (Mayo)Steroids, Anti-TNF, 5-ASA Angelberger S yrs8-11 (Mayo)5-ASA, Probiotics

“Ideal” Populations to Study 1.Early after diagnosis, prior to immunosuppresive therapy 2.Early after Crohn’s resection to prevent endoscopic recurrence 3.Genotype-specific 4.Patients in remission to reduce risk of relapse 5.Proctitis (UC) – mode of administration 6.Pouchitis (UC) 7.Active ileal Crohn’s - ?more dysbiosis driven

Rationale for Earlier Intervention - Window of Inflammation Penetrating Stricturing Cumulative Probability (%) Inflammatory Months Cosnes J, et al. Inflamm Bowel Dis. 2002;8:

Rational for Early Intervention - Dysbiosis is Established Early Gevers D et al Cell Host Microbe Mar 12;15(3):382-92

Rationale for Genotype Enrichment Frank DN, Inflamm Bowel Dis Jan;17(1):179-84

Who to Exclude Food allergies Pregnant Cancer Immunocompromised Cirrhosis History of valvular heart disease

Variables to Control for in Enrolled Population Sommer F, Nat Rev Microbiol Apr;11(4):227-38

Interventions

Variables to Consider for Intervention 1. Dose2. Delivery 3. Duration Stool weight Solution concentration Microbial consituents Aerobe / Anerobic prep Naso-jejnual Enema Colonoscopy Capsule Fresh / Frozen Loading & Maintenance Frequency of administration

Scenarios for Intervention – Parallel Design Study PopulationRandomize 100g Freeze-Thaw FMT Sham FMT 50g Freeze-Thaw FMT Study PopulationRandomize 100g Fresh FMT Probiotics 100g Freeze-Thaw FMT

Scenarios for Intervention – Cross-Over Randomize 100g Freeze-Thaw FMT Sham FMT100g Freeze-Thaw FMT Sham FMT

Solutions to Uncertainties in Intervention 1.Tailor administration to site of inflammation 2.Standard concentration (fecal slurry by donor weight and re-constitution solution) 3.Frozen pre-screened aliquots 4.Regular administration - colonization alone does not guarantee efficacy

Carroll I, PLoS One. 2012; 7(10): e46953 Frozen Donor Stool Retains its Diversity

Single FMT Not Sufficient – Data in Crohn’s Vaughn B, DDW 2014

Outcomes

Clinical Efficacy Outcomes 1.Measure of Response / Remission - endoscopic measure important - Patient Reported Outcomes (PROs) - CDAI, SCCAI no longer convincing alone - Quality of Life 2.Timing of Outcome Assessment - 4 & 8 weeks for response - week 8 and 26 for remission (endoscopic)

Safety Reporting of Adverse Events has been inadequate to date Use of industry-standards for attribution and severity important Long-term surveillance critical (storage of archival donor samples for testing)

Physiological Outcomes Paired diversity assessments (pre- & post-) Metabolomics Inflammatory markers – CRP, Fecal Calprotectin T-cell phenotypes

Weeks FMT 8 Microbiome Sequencing PB T-cell phenotypes LP T-cell phenotypes Clinical / Safety Assessment “Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients Inflammatory Bowel Disease” ClinicalTrials.gov Identifier:NCT

Conclusions FMT should be studied in similar manner to drug therapy to test its efficacy & safety - risk:benefit, cost-effectiveness Challenges – regulatory, funding, standardization Initial promise tempered by variable open-label study outcomes Need for tailored intervention in targeted sub-groups of patients with IBD